Study of TSRA-196 for adults with Alpha-1 Antitrypsin Deficiency
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This trial tests a new medicine called TSRA-196 for people with Alpha-1 Antitrypsin Deficiency who have the PiZZ genetic type. The study looks at whether TSRA-196 can help with lung or liver problems related to this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with Alpha-1 Antitrypsin Deficiency and have the PiZZ genetic type.
- You have a history of low AAT levels in your blood (below 11 µmol/L).
- You have not smoked for at least 6 months and agree not to smoke during the study.
- You are either not currently on AAT treatment, or you have stopped any treatments that affect AAT levels for at least 4 weeks before starting TSRA-196.
- Depending on the study part, you must have either lung disease (like emphysema or bronchiectasis) with mild or no liver scarring, or significant liver scarring (but not cirrhosis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how alpha-1 antitrypsin deficiency affects the liver over time. It aims to learn more about the disease and find better ways to monitor and treat it.
This trial tests a new treatment called CTX460, which is a type of gene therapy that may correct the genetic defect causing alpha-1 antitrypsin deficiency (AATD) and help slow or improve emphysema. It's designed for adults with severe AATD and emphysema who have not had a liver or lung transplant.
This study screens for a rare genetic condition called Alpha-1 Antitrypsin Deficiency in people with lung blockage. It aims to find out if this deficiency is a hidden cause of your breathing problems, which could lead to better treatment options.
This study looks at how alpha-1 antitrypsin deficiency affects the liver in adults. It aims to learn more about the liver problems caused by this condition and may help find better ways to manage them.
This study tests a new gene therapy called KB408 for people with alpha-1 antitrypsin deficiency (AATD). It aims to see if KB408 can help your body produce enough of the missing protein to protect your lungs and liver.
This study checks whether doing alpha-1 screening (genetic test and a blood level test) can help identify alpha-1 antitrypsin deficiency in people at risk. It may be useful if you have symptoms or a family history, but you haven’t had qualifying testing yet.
Hear when a new Alpha 1-antitrypsin Deficiency (AATD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.